Latest Breaking News On - Genvion corporation - Page 1 : comparemela.com

PharmaDrug s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies

PharmaDrug s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert steenRobertj steenSecuredose synthetics incAustralia therapeutic goods administrationSairiyo therapeutics incDrug administrationPharmadrug incGenvion corporationPharmather holdings ltdNewsfile corpSairiyo therapeuticsTherapeutic goods administrationDrug productEnteric coated oral cepharanthineSecuredose synthetics

PharmaDrug Inc : PharmaDrug s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies

PharmaDrug Inc : PharmaDrug s Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesStefan klotterRobertj steenRobert steenGenvion corporationPharmadrug incPharmather holdings ltdNewsfile corpSecuredose synthetics incDrug administrationSairiyo therapeutics incAustralia therapeutic goods administrationSairiyo therapeuticsTherapeutic goods administrationDrug productEnteric coated oral cepharanthine

PharmaDrug appoints Robert Steen as CEO and chairman

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) announced it has appointed seasoned entrepreneur Robert Steen as its new CEO and chairman of the board of directors..

Daniel cohenMichael forbesRobert steenPharmadrug incDrug administrationAustralia therapeutic goods administrationGenvion corporationTrafalgar addiction treatment centresSairiyo therapeuticsTherapeutic goods administration

PharmaDrug Inc : PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Toronto, Ontario (Newsfile Corp. - February 13, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development

United statesWangy cepharanthineDaniel cohenPharmadrug incDrug administrationNational cancer institute surveillanceNewsfile corpAustralia therapeutic goods administrationAustralia researchGenvion corporationAmerican cancer societyTherapeutic goods administrationEnteric coated oral cepharanthineValidated studies reveal potentialEnabling esophageal cancerSairiyo therapeutics

PharmaDrug Inc unveils plans for first-in-human clinical study with its lead drug candidate PD-001 in esophageal cancer

PharmaDrug Inc (CSE:PHRX, OTCQB:LMLLF) revealed that it intends to pursue a first-in-human study of its lead drug candidate cepharanthine-2HCL (PD-001) for.

Daniel cohenAustralia therapeutic goods administrationPharmadrug incAustralia researchDrug administrationGenvion corporationTherapeutic goods administrationInvestigational new drugCurrent good manufacturing practice